184 related articles for article (PubMed ID: 10490345)
1. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Gottdiener JS
Circulation; 1999 Aug; 100(6):685-6. PubMed ID: 10490345
[No Abstract] [Full Text] [Related]
2. Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Thürmann PA
J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S33-6; discussion S41-3. PubMed ID: 10028952
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
Hayashi N; Fujimura Y; Yamamoto S; Kometani M; Nakao K
Arzneimittelforschung; 1997 May; 47(5):625-9. PubMed ID: 9205776
[TBL] [Abstract][Full Text] [Related]
4. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
Kometani M; Hayashi N; Yamamoto S; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
[TBL] [Abstract][Full Text] [Related]
6. [Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives].
Weisser B; Vetter H; Mengden T
Dtsch Med Wochenschr; 2003 Mar; 128(11):541-4. PubMed ID: 12635025
[TBL] [Abstract][Full Text] [Related]
7. Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy.
Kondrack R; Mohiuddin S
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1125-34. PubMed ID: 19689218
[TBL] [Abstract][Full Text] [Related]
8. Valsartan plus hydrochlorothiazide for first-line therapy in hypertension.
Lacourcière Y; Poirier L; Samuel R
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1491-501. PubMed ID: 19954310
[TBL] [Abstract][Full Text] [Related]
9. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
10. Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
Ke YS; Cao H; Yang T
Acta Pharmacol Sin; 2000 Nov; 21(11):1043-7. PubMed ID: 11501062
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Thürmann PA
Cardiology; 1999; 91 Suppl 1():3-7. PubMed ID: 10449888
[TBL] [Abstract][Full Text] [Related]
13. [Morphofunctional characteristics of myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of angiotensin II].
Frolov VA; Drozdova GA; Mustiatsa VF; Balaev VV
Dokl Akad Nauk; 1999 May; 366(3):413-5. PubMed ID: 10420261
[No Abstract] [Full Text] [Related]
14. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication: hemodynamic effects of valsartan in dog heart failure models.
Yamamoto S; Hayashi N; Kometani M; Nakao K
Arzneimittelforschung; 1997 May; 47(5):630-4. PubMed ID: 9205777
[TBL] [Abstract][Full Text] [Related]
15. The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats.
Kassab S; Garadah T; Abu-Hijleh M; Golbahar J; Senok S; Wazir J; Gumaa K
J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):206-11. PubMed ID: 17318789
[TBL] [Abstract][Full Text] [Related]
16. [New prospects in the treatment of arterial hypertension. Antagonist of angiotensin II valsartan (diovan)].
Ivleva AIa
Ter Arkh; 1998; 70(9):85-8. PubMed ID: 9821238
[No Abstract] [Full Text] [Related]
17. New angiotensin-II blocker.
Lilley LL; Guanci R
Am J Nurs; 1996 Mar; 96(3):20. PubMed ID: 8607540
[No Abstract] [Full Text] [Related]
18. [Myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of formation of angiotensin II and its interaction with specific receptors].
Frolov VA; Drozdova GA; Mustiatsa VF; Balaev VV; Rieger P
Biull Eksp Biol Med; 1999 May; 127(5):506-9. PubMed ID: 10399566
[No Abstract] [Full Text] [Related]
19. Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis.
Tachikawa H; Kodama M; Hui L; Yoshida T; Hayashi M; Abe S; Kashimura T; Kato K; Hanawa H; Watanabe K; Nakazawa M; Aizawa Y
J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S105-10. PubMed ID: 12688405
[TBL] [Abstract][Full Text] [Related]
20. Valsartan: a novel angiotensin type 1 receptor antagonist.
Thürmann PA
Expert Opin Pharmacother; 2000 Jan; 1(2):337-50. PubMed ID: 11249553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
